Metagenomi Therapeutics, Inc. MGX
0.61 USD -0.02 (-3.45%)
As ofNov 19, 2026, 3:49 PM EST
0.61 Day range 0.6423
0.60 52-week range 1.87
- YTD
- -62.35%
- 1 year
- -62.11%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 18.40 +2916.4% upside
Now 0.61
- Target (low)
- 14.00
- Target (mean)
- 18.40
- Target (high)
- 25.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy1
- Buy4
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 7
- 2 months ago 7
- 3 months ago 7
Included in Essentials and up
Sign in to see Revenue and earnings forecast
Reported revenue and earnings per share by year, then what analysts expect next.
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.58333 | -0.66 – -0.45 | -9.91 | +94.1% | 9.46M | -23.7% | 3 |
| Next quarter | -0.69 | -0.71 – -0.67 | -2.08 | +66.8% | 6.25M | -44.0% | 2 |
| Current year | -2.48 | -2.84 – -2.17 | -36.49 | +93.2% | 51.63M | +15.3% | 4 |
| Next year | -2.88 | -3.26 – -2.60 | -2.48 | -16.0% | 33.16M | -35.8% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 21, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Nov 20, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Oct 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 6, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 5, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 19, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Aug 15, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Jul 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 15, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 7, 2024 | HC Wainwright & Co. | Initiated | — | Buy |
| May 2, 2024 | JP Morgan | Downgrade | Overweight | Neutral |
| Mar 28, 2024 | Chardan Capital | Maintained | Buy | Buy |
| Mar 5, 2024 | TD Cowen | Initiated | — | Outperform |
| Mar 5, 2024 | Wells Fargo | Initiated | — | Overweight |
| Mar 5, 2024 | JP Morgan | Initiated | — | Overweight |
| Mar 5, 2024 | Jefferies | Initiated | — | Buy |
| Mar 5, 2024 | BMO Capital | Initiated | — | Outperform |
| Mar 5, 2024 | Chardan Capital | Initiated | — | Buy |
Included in Plus and up
Sign in to see Analyst trend
Two years of the analyst rating mix and the average price target against the price.
